# Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

> **NCT05593185** · — · AVAILABLE · sponsor: **Sellas Life Sciences Group**

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** Galinpepimut-S

## Key facts

- **NCT ID:** NCT05593185
- **Lead sponsor:** Sellas Life Sciences Group
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593185, "Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05593185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*